Cargando…
Epigenetic therapy for ovarian cancer: promise and progress
Ovarian cancer is the deadliest gynecologic malignancy, with a 5-year survival rate of approximately 47%, a number that has remained constant over the past two decades. Early diagnosis improves survival, but unfortunately only 15% of ovarian cancers are diagnosed at an early or localized stage. Most...
Autores principales: | Moufarrij, Sara, Dandapani, Monica, Arthofer, Elisa, Gomez, Stephanie, Srivastava, Aneil, Lopez-Acevedo, Micael, Villagra, Alejandro, Chiappinelli, Katherine B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334391/ https://www.ncbi.nlm.nih.gov/pubmed/30646939 http://dx.doi.org/10.1186/s13148-018-0602-0 |
Ejemplares similares
-
Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
por: Moufarrij, Sara, et al.
Publicado: (2020) -
Author Correction: Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
por: Moufarrij, Sara, et al.
Publicado: (2021) -
Editorial: Genetic and Epigenetic Control of Immune Responses
por: Noonepalle, Satish kumar R., et al.
Publicado: (2021) -
Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
por: Banik, Debarati, et al.
Publicado: (2019) -
Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer
por: Gomez, Stephanie, et al.
Publicado: (2022)